Comparing CRISPR Therapeutics (NASDAQ:CRSP) & aTyr Pharma (NASDAQ:ATYR)

CRISPR Therapeutics (NASDAQ:CRSP) and aTyr Pharma (NASDAQ:ATYR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings for CRISPR Therapeutics and aTyr Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1	7	9	2	2.63
aTyr Pharma	1	0	1	1	2.67

CRISPR Therapeutics presently has a consensus price target of $65.75, indicating a potential upside of 29.65%. Given CRISPR Therapeutics’ higher possible upside, equities research analysts clearly believe CRISPR Therapeutics is more favorable than aTyr Pharma.

Insider and Institutional Ownership

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 5.0% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares CRISPR Therapeutics and aTyr Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
aTyr Pharma	N/A	-95.89%	-69.67%

Risk and Volatility

CRISPR Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Earnings & Valuation

This table compares CRISPR Therapeutics and aTyr Pharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51 million	1,396.96	-$581.60 million	($4.76)	-10.65
aTyr Pharma	$190,000.00	83.63	-$74.12 million	($24.80)	-0.26

aTyr Pharma has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

CRISPR Therapeutics beats aTyr Pharma on 11 of the 15 factors compared between the two stocks.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

About aTyr Pharma

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.